Brief: Santhera To Discontinue Phase 3 Sideros Study And Focus On Vamorolone

Santhera Pharmaceuticals Holding AG

06/10/2020 06:07

Oct 6 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG
 SANN.S :
    * SANTHERA TO DISCONTINUE PHASE 3 SIDEROS STUDY AND
DEVELOPMENT OF
PULDYSA® IN DUCHENNE MUSCULAR DYSTROPHY (DMD) AND FOCUS ON
VAMOROLONE
    * SANTHERA PHARMACEUTICALS HOLDING AG - DATA FROM AN INTERIM
ANALYSIS CONDUCTED BY INDEPENDENT DATA AND SAFETY MONITORING
BOARD (DSMB) CONCLUDED THAT STUDY WAS UNLIKELY TO MEET ITS
PRIMARY ENDPOINT
    * SANTHERA PHARMACEUTICALS HOLDING AG - INTENDS TO INITIATE
A
RESTRUCTURING PLAN FOR BUSINESS WITH A FOCUS ON RETAINING KEY
FUNCTIONS FOR BRINGING DMD DRUG CANDIDATE VAMOROLONE TO PATIENTS
AND EXECUTE ON ITS OTHER PIPELINE PROGRAMS

Source text for Eikon:  ID:nGNE48MzQm 
Further company coverage:  SANN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))